GCA
MRNA icon

Gallagher Capital Advisors’s Moderna MRNA Stock Holding History

Gallagher Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.98M Buy
+11,652
New +$1.26M 3.2% 9

Other funds holding MRNA

DLA
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
LHWM
Lake Hills Wealth Management Austin, Texas $218M AUM 31.66% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Gallagher Capital Advisors's MRNA Position: Q3 2026 in Review

Gallagher Capital Advisors opened a new position in Moderna (MRNA) in Q3 2026: 11,652 shares worth $5.98M. The stake represents 3.2% of the portfolio and ranks #9 among its holdings.

32 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Gallagher Capital Advisors held 11,652 shares of Moderna worth $5.98M as of Q3 2026.
  • Moderna was a new Gallagher Capital Advisors position in Q3 2026.
  • Moderna made up 3.2% of Gallagher Capital Advisors's portfolio in Q3 2026, its #9 holding.
  • 32 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Gallagher Capital Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.